Evolving Treatment Landscape in Myelodysplastic Syndromes - Episode 12

Cytopenias Following Imetelstat Treatment in Lower-Risk MDS

March 5, 2024

Andrew Brunner, MD, Amy DeZern, MD, MHS, Ehab L. Atallah, MD, Yasmin Abaza, MD

An MDS specialist discusses cytopenias associated with imetelstat treatment in patients with lower-risk MDS, highlighting findings from the IMerge clinical trial.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Diagnosis of Myelodysplastic Syndromes (MDS)

EP. 2: Risk Stratification of Myelodysplastic Syndromes

EP. 3: First-Line Treatment of Lower-Risk MDS with Symptomatic Anemia

EP. 4: Patient Profile 1: A 72-Year-Old Man With MDS

EP. 5: Second-Line Treatment of Lower-Risk MDS With Symptomatic Anemia

EP. 6: Patient Profile 2: A 77-Year-Old Man With MDS

EP. 7: Unmet Needs and Adverse Event Management for Patients With Lower-Risk MDS and Symptomatic Anemia

EP. 8: ESA Treatment Selection in MDS

EP. 9: Updates from COMMANDS Trial: Luspatercept in Lower-Risk MDS

EP. 10: Retrospective Claims Data and Patient Reported-Outcomes from COMMANDS Trial in Lower-Risk MDS

EP. 11: IMerge: Imetelstat in Patients With Lower-Risk MDS

Now Viewing

EP. 12: Cytopenias Following Imetelstat Treatment in Lower-Risk MDS

EP. 13: Emerging Clinical Trials in MDS and Key Takeaways from ASH 2023

EP. 14: Treatment Options and Unmet Needs in Higher-Risk MDS

EP. 15: Updates from ASH 2023 in Higher-Risk MDS

EP. 16: Takeaways from ASH 2023 in Higher-Risk MDS

EP. 17: Closing Thoughts on the MDS Treatment Landscape